Amneal Eyes Generic Injectables Deals, While Competition Bites Sooner Than Anticipated
A strengthened cash position has provided Amneal the chance to seek inorganic opportunities to bolster its growing presence in injectables. The US-based, US-centric company is looking to grow its operations, having been surprised in recent weeks by generic competition to its most lucrative generic assets.
You may also be interested in...
Pricing pressures that have affected the US generics market over the last few years have stabilized and this will continue to be the case in the future, according to Teva chief Kåre Schultz. Speaking at the 2019 J.P. Morgan Healthcare Conference, he also revealed that the firm was on track with its restructuring and debt-reduction plan.
Generics Bulletin previews the most notable and anticipated events for October 2023.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.